CRISPRMED25
The 2nd CRISPR MEDiCiNE Conference, April 7-11th, 2025

Go to the Official CRISPRMED25 website

  • Meet the global CRISPR Medicine community in Copenhagen, Denmark April 7-11th, 2025.
  • Focus: Tools, Delivery, Safety/Off-target, Diseases, Pre-clinical/clinical, Standards and Regulations | Functional Genomics, Target Identification, Target Validation.
  • Segments: University, Hospital, Biotech, Pharma, CRO.
  • Scientific conference: +500 delegates, +60 speakers, +150 poster presenters, 2x poster sessions, 30 sponsors, relevant workshops, social and networking events
  • Startup-Investor event (new in 2025): "Invest in Future CRISPR Medicine | Develop Future Medicine". Meet the early-stage startups and the investors, B2B networking
  • Opportunity to meet one of the first CRISPR medicine patients.
  • Venue Site: Øksnehallen, Copenhagen, Denmark.
  • Organiser: CRISPR Medicine News, CMN.

Check out CRISPRMED24 for inspiration and CMN LinkedIn for the stories.

CRISPRMED25 Speakers (early confirmation)

Scientific Conference (virtual, April 7, 2025 | in-person, April 8-11, 2025)

 

Keynote Speaker: Virginijus Šikšnys, Prof., Ph.D., Head of Department, Vilnius University, Lithuania

Patient Advocate: Jimi Olaghere is a CASGEVY recipient who has developed a keen interest in the advancements of cell and gene therapies, since his transformative participation in the groundbreaking clinical trial. Jimi is passionate about the positive impact that these therapies can have on patients in need and has become a staunch advocate for increased accessibility of gene therapies for sickle cell disease patients worldwide. At CRISPRMED25, Jimi will share his story about living with sickle cell disease, before and after treatment with the recently approved CRISPR therapy CASGEVY.

  • Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England
  • Alvin Luk, Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc., US
  • Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
  • Annarita Miccio, Group Leader, Ph.D., Imagine Institute of Genetic Diseases, France
  • Attila Sebe, MD, PhD (Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany)
  • Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel
  • Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida Therapeutics, US
  • Daniel Siegwart, Ph.D., Prof., University of Texas Southwestern Medical Center, United States
  • Dolça Rogers, Ph.D., ATMP topic lead, Pharmaceutical Quality Office, European Medicines Agency (EMA), Netherlands
  • Emma Wang, Ph.D., CTO, YolTech Therapeutics, China
  • Gerald Schwank, Prof., Ph.D., University of Zürich, Switzerland
  • Guillermo Montoya, Prof., Research Director and Group Leader at the Protein Structure and Function program at CPR, University of Copenhagen, Denmark
  • Jacob Corn, Prof., Ph.D., ETH Zürich, Switzerland
  • Jakob Giehm Mikkelsen, Prof., Ph.D., Aarhus University, Denmark
  • Jakob Nilsson, Prof., Ph.D., Danish Cancer Institute, Copenhagen, Denmark
  • Julian Grünewald, Ass. Prof., MD, Ph.D., Technical University of Munich, Germany
  • Karim Benabdel Lah El Khlanji, Senior Scientist at the GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain, GeneHumdi Action Chair
  • Kiana Aran, Associate Professor of Bioengineering and Medicine, University of California San Diego, US
  • Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
  • Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, US
  • Özcan Met, Ph.D., Associate Professor and Head of Cell Therapy Unit at the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev University Hospital and DTU HealthTech, Denmark
  • Raffaella Di Micco, Group Leader, Ph.D., SR-TIGET, Italy
  • Rasmus O. Bak, Ass. Prof. and Group Leader, Aarhus University, Denmark
  • Rob Wolthuis, Ph.D., Associate Prof., Amsterdam UMC, Netherlands
  • Suk See De Ravin, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US
  • Thorsten Stafforst, Ph.D., Professor at Interfaculty Institute of Biochemistry at the University of Tuebingen, Germany.
  • William H. Peranteau, MD, Surgeon and Professor, University of Pennsylvania/Children’s Hospital of Philadelphia, US
  • Xavier Duportet, Ph.D., CEO and Co-founder, Eligo Biosciences
  • TBD, Life Edit Therapeutics, US
  • TBD, ReCode Therapeutics, US

Startup-Investor Event "Invest in Future CRISPR Medicine | Develop Future Medicine" (in-person, April 8, 2025)

Go to the Official CRISPRMED25 website to see the full updated list

CRISPRMED25 Scientific Committee
  • ​​​​​​Alessia Cavazza, Ass. Prof., Group Leader, University College London's Great Ormond Street Institute of Child Health, England
  • Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
  • Karim Benabdel Lah El Khlanji, Senior Scientist at the GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain, GeneHumdi Action Chair
  • Rasmus O. Bak, Tenured Associate Professor at the Department of Biomedicine at Aarhus University, Co-founder of UNIKUM Therapeutics, Denmark
  • Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
  • Ayal Hendel, Principal Investigator at The Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University, Israel
  • Karen O´Hanlon Cohrt, Chief Editor CRISPR Medicine News, CMN
Stay Updated

Stay updated about the program - sign up to the CRISPRMED25 Newsletter.

Sorry - something went wrong, your inquiry has not been sent!!
Thanks for your interest for The 2nd CRISPR Medicine Conference 2025. We will soon share more details.

Terms and Conditions
The CRISPRMED25 Newsletter is published by CRISPR Medicine Media Aps organiser of the CRISPR Medicine Conference. The CRISPR Medicine Media team is committed to protecting and respecting my privacy. CRISPR Medicine Media will guard my information responsibly and never share my email address. When I subscribe to the CRISPRMED25 Newsletter via this online form or email, I consent to CRISPR Medicine Media registering my email address to deliver email content.I may revoke my consent at any given time. CRISPR Medicine Media will delete my contact details when I terminate my subscription.

Interested to learn more about the Sponsorship or Exhibitor Packages?

Sponsorship packages and limited number of exhibitor spaces will be available at CRISPRMED25. Contact us today to learn more.

Sorry - something went wrong, your inquiry has not been sent!!
Thanks for your interest for The 2nd CRISPR Medicine Conference 2025. We will soon share more details.
CRISPRMED25 Supporters (early confirmation)

View the full list here

 

CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25 Supporters (early confirmation)
CRISPRMED25
CRISPRMED25
CRISPRMED25
close
Search CRISPR Medicine